In an advance that could significantly lighten the load for caretakers in the “sandwich generation” and reduce loneliness in elderly patients, Aspargo Labs Inc. developed a metered delivery device that optimizes absorption of pharmaceuticals and reminds users to take their medications.
Michael Demurjian, CEO of Aspargo Labs, discusses with Pharmaceutical Executive how their proprietary technology transforms traditional oral medications into liquid doses, improving delivery, absorption, and patient outcomes.
CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.
Aspargo Labs (AAGO) has filed to go public via a direct offering. The New York-based company, known for its liquid drug formulations and delivery devices, aims to list on the NYSE, with its lead product, a liquid sildenafil citrate formulation, approved in Europe.